Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization

Journal of Clinical Investigation

Volumn 118, Issue 4, 2008, Pages 1380-1389

  Chakroborty, Debanjan ^a,b   Chowdhury, Uttio Roy ^a   Sarkar, Chandrani ^a,b   Baral, Rathindranath ^a   Dasgupta, Partha Sarathi ^a   Basu, Sujit ^a,b,c  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL FUNCTION; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; LOW DRUG DOSE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; STEM CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD45; BONE MARROW; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOPAMINE; ENDOTHELIAL CELLS; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RECEPTORS, DOPAMINE D2; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 41849138680     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33125     Document Type: Article

References (44)

1. Folkman, J. 2002. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl. 16):15-18.
2. Dvorak, H.F. 2005. Angiogenesis: update 2005. J. Thromb. Haemost. 3:1835-1842.
3. Ferrara, N., and Kerbel, R.S. 2005. Angiogenesis as a therapeutic target. Nature. 438:967-974.
4. Asahara, T., et al. 1999. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85:221-228.
5. Lyden, D., et al. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-1201.
6. Ho, J.W., et al. 2006. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology. 44:836-843.
7. Dome, B., et al. 2006. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 66:7341-7347.
8. Kopp, H.G., Ramos, C.A., and Rafii, S. 2006. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 13:175-181.
9. Batchelor, T.T., et al. 2007. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 11:83-95.
10. Heissig, B., et al. 2002. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 109:625-637.
11. Rabbany, S.Y., Heissig, B., Hattori, K., and Rafii, S. 2003. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol. Med. 9:109-117.
12. Hristov, M., Erl, W., and Weber, P.C. 2003. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler. Thromb. Vasc. Biol. 23:1185-1189.
13. Yu, D., et al. 2007. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin. Cancer Res. 13:3814-3824.
14. Duda, D.G., et al. 2006. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood. 107:2774-2776.
15. Basu, S., et al. 2001. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 7:569-574.
16. Sarkar, C., et al. 2004. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 287:H1554-H1560.
17. Marino, F., et al. 1997. Measurement of catecholamines in mouse bone marrow by means of HPLC with electrochemical detection. Haematologica. 82:392-394.
18. Amano, H., et al. 2003. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197:221-232.
19. Cui, Z. 2003. The winding road to the discovery of the SR/CR mice. Cancer Immun. 3:14.
20. Capillo, M., et al. 2003. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin. Cancer Res. 9:377-382.
21. Fürstenberger, G., et al. 2006. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer. 94:524-531.
22. Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., and Caron, M.G. 1998. Dopamine receptors: from structure to function. Physiol. Rev. 78:189-225.
23. Zaroslinski, J.F., et al. 1977. The pharmacology and subacute toxicology of dopamine. Proc. R. Soc. Med. 70(Suppl. 2):2-6.
24. Lin, Y., Weisdorf, D.J., Solovey, A., and Hebbel, R.P. 2000. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105:71-77.
25. Beck, J.A., et al. 2000. Genealogies of mouse inbred strains. Nat. Genet. 24:23-25.
26. Schuch, G., et al. 2003. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of ensothelial progenitor cells. Cancer Res. 63:8345-8350.
27. Asahara, T., et al. 1999. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:3964-3972.
28. Vu, T.H., and Werb, Z. 2000. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14:2123-2133.
29. Ribatti, D. 2004. The involvement of endothelial progenitor cells in tumor angiogenesis. J. Cell. Mol. Med. 8:294-300.
30. Lai, W.C., Zhou, M., Shankavaram, U., Peng, G., and Wahl, L.M. 2003. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J. Immunol. 170:6244-6249.
31. Hong, S., et al. 2005. Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on the invasion of renal carcinoma cells. J. Biol. Chem. 280:25202-25209.
32. Moshal, K.S., et al. 2006. Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am. J. Physiol. Cell Physiol. 290:C883-C891.
33. Li, B., et al. 2006. VEGF and PIGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 20:1495-1497.
34. Spring, H., Schüler, T., Arnold, B., Hämmerling, G.J., and Ganss, R. 2005. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. U. S. A. 102:18111-18116.
35. Gao, D., et al. 2008. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 319:195-198.
36. Spiegel, A., et al. 2007. Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling. Nat. Immunol. 8:1123-1231.
37. Rohde, E., et al. 2006. Blood monocytes mimic endothelial progenitor cells. Stem Cells. 24:357-367.
38. Flierl, M.A., et al. 2007. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature. 449:721-725.
39. Shantsila, E., Watson, T., and Lip, G.Y. 2007. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol. 49:741-752.
40. Basu, S., et al. 2004. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 64:5551-5555.
41. Chakroborty, D., et al. 2004. Depleted dopamine in gastric cancer tissues: dopamine treatment retards-growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 10:4349-4356.
42. Katzung, B. 2003. Basic and clinical pharmacology. 9th edition. Appleton & Lange. Norwalk, Connecticut, USA. 1088 pp.
43. Kato, T., Sato, K., Kakinuma, H., and Matsuda, Y. 1994. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res. 54:5143-5147.
44. Prewett, M., et al. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:5209-5218.